Breast Unit, Department of Surgical Science, PTV: Policlinico Tor Vergata University, Rome, Italy.
Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilia, Modena, Italy.
Anticancer Res. 2020 Dec;40(12):7119-7125. doi: 10.21873/anticanres.14741. Epub 2020 Dec 7.
BACKGROUND/AIM: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation.
All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group.
A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown and Pre-lockdown-groups, respectively. At univariate analysis, waiting times, lymph-nodes involvement and cancer grading, showed a statistically significant difference (p<0.05). Multivariate analysis identified waiting-time on list (OR=1.07) as a statistically significant predictive factor of lymph node involvement.
Although we did not observe a clinically evident difference in breast cancer presentation, we reported an increase in lymph node involvement.
背景/目的：旨在限制 SARS-CoV-2 传播的特殊限制措施；它们对医疗系统进行了全面重组。肿瘤治疗明显放缓。我们的多中心回顾性研究旨在评估 COVID-19 期间筛查暂停和手术治疗延迟及其对乳腺癌表现的影响。
评估了所有于 2020 年 3 月 11 日至 2020 年 5 月 30 日接受乳房手术的患者，并将其视为封锁组。将这些患者与前一年的类似患者（前封锁组）进行比较。
共评估了 432 名患者；封锁组和前封锁组分别为 223 名和 209 名。单因素分析显示，等待时间、淋巴结受累和癌症分级存在统计学显著差异（p<0.05）。多因素分析确定等待时间是淋巴结受累的统计学显著预测因素（OR=1.07）。
尽管我们没有观察到乳腺癌表现方面的临床明显差异，但我们报告淋巴结受累增加。
